These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 8919060

  • 1. Addition of the (28-38) peptide sequence of PACAP to the VIP sequence modifies peptide selectivity and efficacy.
    Gourlet P, Vandermeers A, Vandermeers-Piret MC, De Neef P, Robberecht P.
    Int J Pept Protein Res; 1996 Oct; 48(4):391-6. PubMed ID: 8919060
    [Abstract] [Full Text] [Related]

  • 2. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
    Van Rampelbergh J, Gourlet P, De Neef P, Robberecht P, Waelbroeck M.
    Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
    [Abstract] [Full Text] [Related]

  • 3. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
    Solano RM, Carmena MJ, Carrero I, Cavallaro S, Roman F, Hueso C, Travali S, Lopez-Fraile N, Guijarro LG, Prieto JC.
    Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
    [Abstract] [Full Text] [Related]

  • 4. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
    Gourlet P, Rathé J, De Neef P, Cnudde J, Vandermeers-Piret MC, Waelbroeck M, Robberecht P.
    Eur J Pharmacol; 1998 Jul 31; 354(1):105-11. PubMed ID: 9726637
    [Abstract] [Full Text] [Related]

  • 5. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation.
    Hashimoto H, Ogawa N, Hagihara N, Yamamoto K, Imanishi K, Nogi H, Nishino A, Fujita T, Matsuda T, Nagata S, Baba A.
    Mol Pharmacol; 1997 Jul 31; 52(1):128-35. PubMed ID: 9224822
    [Abstract] [Full Text] [Related]

  • 6. Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes.
    Gourlet P, Vandermeers-Piret MC, Rathé J, De Neef P, Cnudde J, Robberecht P, Waelbroeck M.
    Eur J Pharmacol; 1998 May 01; 348(1):95-9. PubMed ID: 9650836
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.
    Simonneaux V, Kienlen-Campard P, Loeffler JP, Basille M, Gonzalez BJ, Vaudry H, Robberecht P, Pévet P.
    Neuroscience; 1998 Aug 01; 85(3):887-96. PubMed ID: 9639281
    [Abstract] [Full Text] [Related]

  • 8. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.
    Gourlet P, Vertongen P, Vandermeers A, Vandermeers-Piret MC, Rathe J, De Neef P, Waelbroeck M, Robberecht P.
    Peptides; 1997 Aug 01; 18(3):403-8. PubMed ID: 9145428
    [Abstract] [Full Text] [Related]

  • 9. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
    Zawilska JB, Dejda A, Niewiadomski P, Gozes I, Nowak JZ.
    J Mol Neurosci; 2005 Aug 01; 25(3):215-24. PubMed ID: 15800375
    [Abstract] [Full Text] [Related]

  • 10. Structural motifs of pituitary adenylate cyclase-activating polypeptide (PACAP) defining PAC1-receptor selectivity.
    Schäfer H, Zheng J, Morys-Wortmann C, Fölsch UR, Schmidt WE.
    Regul Pept; 1999 Feb 05; 79(2-3):83-92. PubMed ID: 10100920
    [Abstract] [Full Text] [Related]

  • 11. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide stimulate two signaling pathways in CHO cells stably transfected with the selective type I PACAP receptor.
    Delporte C, Poloczek P, de Neef P, Vertongen P, Ciccarelli E, Svoboda M, Herchuelz A, Winand J, Robberecht P.
    Mol Cell Endocrinol; 1995 Jan 05; 107(1):71-6. PubMed ID: 7796937
    [Abstract] [Full Text] [Related]

  • 12. Identification of a VIP-specific receptor in guinea pig tenia coli.
    Teng BQ, Grider JR, Murthy KS.
    Am J Physiol Gastrointest Liver Physiol; 2001 Sep 05; 281(3):G718-25. PubMed ID: 11518684
    [Abstract] [Full Text] [Related]

  • 13. Characterization of ocular receptors for pituitary adenylate cyclase activating polypeptide (PACAP) and their coupling to adenylate cyclase.
    Nilsson SF, De Neef P, Robberecht P, Christophe J.
    Exp Eye Res; 1994 Apr 05; 58(4):459-67. PubMed ID: 7925682
    [Abstract] [Full Text] [Related]

  • 14. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
    Zawilska JB, Niewiadomski P, Nowak JZ.
    Pol J Pharmacol; 2004 Apr 05; 56(2):203-11. PubMed ID: 15156071
    [Abstract] [Full Text] [Related]

  • 15. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
    Zawilska JB, Niewiadomski P, Nowak JZ.
    Gen Comp Endocrinol; 2004 Jun 05; 137(2):187-95. PubMed ID: 15158130
    [Abstract] [Full Text] [Related]

  • 16. Receptors for pituitary adenylate cyclase-activating peptide in human liver.
    Guijarro LG, Rodriguez-Henche N, García-López E, Noguerales F, Dapena MA, Juarranz MG, Prieto JC.
    J Clin Endocrinol Metab; 1995 Aug 05; 80(8):2451-7. PubMed ID: 7629241
    [Abstract] [Full Text] [Related]

  • 17. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors in chick cerebral cortex.
    Zawilska JB, Niewiadomski P, Nowak JZ.
    J Mol Neurosci; 2003 Apr 05; 20(2):153-62. PubMed ID: 12794309
    [Abstract] [Full Text] [Related]

  • 18. Cloning and expression of a complementary DNA encoding the bovine receptor for pituitary adenylate cyclase-activating polypeptide (PACAP).
    Miyamoto Y, Habata Y, Ohtaki T, Masuda Y, Ogi K, Onda H, Fujino M.
    Biochim Biophys Acta; 1994 Aug 02; 1218(3):297-307. PubMed ID: 8049255
    [Abstract] [Full Text] [Related]

  • 19. Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors.
    Gourlet P, Vandermeers A, Vandermeers-Piret MC, Rathé J, De Neef P, Robberecht P.
    Eur J Pharmacol; 1995 Dec 04; 287(1):7-11. PubMed ID: 8666028
    [Abstract] [Full Text] [Related]

  • 20. Expression, pharmacological, and functional evidence for PACAP/VIP receptors in human lung.
    Busto R, Carrero I, Guijarro LG, Solano RM, Zapatero J, Noguerales F, Prieto JC.
    Am J Physiol; 1999 Jul 04; 277(1):L42-8. PubMed ID: 10409229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.